Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 8/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
| ▸ | PPID | Q08752 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8527866 | 0.87 | EGLN1 (0.47) | HPGDEGLN1TP53ALDH1A1KDM4E | |
| SCHEMBL12828250 | 0.85 | HPGD (0.43) | HPGDEGLN1TP53ALDH1A1KDM4E | |
| SCHEMBL8517219 | 0.84 | PTGER1 (0.47) | HPGDEGLN1PTGER1KMT2AMEN1 | |
| SCHEMBL15744035 | 0.83 | PTGER1 (0.44) | EGLN1PTGER1MAPTL3MBTL1POLB | |
| SCHEMBL12828314 | 0.82 | ALDH1A1 (0.40) | HPGDEGLN1TP53ALDH1A1MAPT | |
| SCHEMBL12828563 | 0.82 | EGLN1 (0.40) | HPGDEGLN1TP53ALDH1A1KDM4E | |
| SCHEMBL8517633 | 0.81 | PTGER1 (0.41) | HPGDEGLN1ALDH1A1KDM4EPTGER1 | |
| SCHEMBL12828564 | 0.81 | EGLN1 (0.50) | HPGDEGLN1TP53ALDH1A1KDM4E | |
| SCHEMBL8527906 | 0.78 | RIPK1 (0.42) | HPGDTP53ALDH1A1KDM4ENPSR1 | |
| SCHEMBL8522602 | 0.77 | EGLN1 (0.38) | EGLN1MAPTL3MBTL1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145254-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | JAPAN TOBACCO INC. (JP) | 2016-05-26 | — | — | US | disclosed |
| EP-2455381-B9 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER | JAPAN TOBACCO INC (JP) | 2014-10-22 | — | — | EP | disclosed |
| EP-2455381-B1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER | JAPAN TOBACCO INC (JP) | 2014-05-28 | — | — | EP | disclosed |
| US-20130096155-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | JAPAN TOBACCO INC. (JP) | 2013-04-18 | — | — | US | disclosed |
| US-8283465-B2 | Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent | JAPAN TOBACCO INC. (JP) | 2012-10-09 | — | — | US | disclosed |
| EP-2455381-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER | Japan Tobacco, Inc. (JP) | 2012-05-23 | — | — | EP | disclosed |
| US-20110077267-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | JAPAN TOBACCO INC. (JP) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096155-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | EGLN3, EPOR, EGLN2 | HPGD 220/4885EGLN1 8/4885TP53 1262/4885 |
| US-20110077267-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | EGLN3, EPOR, EGLN2 | HPGD 220/4885EGLN1 8/4885TP53 1262/4885 |
| US-20160145254-A1 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT | EGLN3, EPOR, EGLN2 | HPGD 220/4885EGLN1 8/4885TP53 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.